What is the ticker symbol for Immunocore?

Immunocore trades under the ticker IMCR on NASDAQ.

What sector does Immunocore operate in?

Immunocore is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze IMCR in a portfolio?

PortView shows IMCR's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Immunocore (IMCR) Stock Analysis

NASDAQHealthcareBiotechnology

$36.72-0.38%

1-year price historyRange $27.79 – $40.22

52-week range$36.72

$27.56$40.72

What Immunocore does

Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.

Key metrics

Market cap

$1.87B

P/E (TTM)

-103.60

EPS (TTM)

$-0.35

Beta

0.74

Dividend yield

0.00%

Revenue / share

$7.92

50-day avg

$34.03

200-day avg

$32.75

52-week high

$40.72

52-week low

$27.56

CEO

Bahija Jallal

ETFs linked to IMCR

Broad-market and Healthcare sector ETFs an investor holding Immunocore is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how IMCR fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze IMCR in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Immunocore?: Immunocore trades under the ticker IMCR on NASDAQ.
Which exchange is IMCR listed on?: IMCR is listed on NASDAQ.
What sector does Immunocore operate in?: Immunocore is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze IMCR in a portfolio?: PortView shows IMCR's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.